MarginsXMarginsX
Home › Markets › Health Care › VKTX

Viking Therapeutics Inc. (VKTX)

VKTX trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$26.80
-8.28% on the day
Market cap
$3.4B
Mid cap
Revenue · 2025
$0
Prior year not contiguous
Net income · 2025
-$359.6M

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1607678/000119312526046876/0001193125-26-046876-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerVKTX on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2015
SEC CIK0001607678
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials · 2025

LineValue
Revenue$0
Net income-$359.6M
Operating income-$393.3M
Net marginNeeds revenue and net income
Operating marginOperating income not reported
Revenue growthNo prior-year revenue to compare
Cash$165.8M
Total assets$715.7M
P/E (computed)Net income was not positive
P/S (computed)Needs market cap and revenue

Warning signs

Cash runway
17.6 months
$677.6M cash at September 30, 2026
Share count, 1 year
+12.8%
2025-10-15 to 2026-10-15 · +27.5% over 3 years
Going-concern doubt
No
10-Q filed October 29, 2026
Insider net buying, 12 months
-$21.9M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-10-29
Cash and burn$677.6M cash; operating cash flow -$115.7M a quarter.Report 2026-09-30
Shares outstanding127,522,189 (2026-10-15); 113,036,344 a year earlier; 100,028,953 three years earlier.Cover page 2026-10-15
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 4 424B5 takedowns, 4 at the marketLatest 2026-09-25
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorCBIZ CPAs P.C., Costa Mesa, California, United States; changed auditors 1 time in 24 months8-K 4.01 2025-04-23
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $150K, sold $22.0M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$0-$183.2M-$138.2M$677.6MNo debt tags$010-Q 2026-10-29
Q2 2026
2026-06-30
$0-$128.0M-$125.2M$125.8MNo debt tags$010-Q 2026-07-29
Q1 2026
2026-03-31
$0-$158.3M-$114.0M$118.1MNo debt tags$010-Q 2026-04-30
Q4 2025
2025-12-31
$0-$157.7M-$85.3M$165.8MNo debt tags$010-K 2026-02-11
Q3 2025
2025-09-30
$0-$90.8M-$94.0M$100.4MNo debt tags$010-Q 2026-10-29
Q2 2025
2025-06-30
$0-$65.6M-$47.1M$33.9MNo debt tags$010-Q 2026-07-29
Q1 2025
2025-03-31
$0-$45.6M-$52.3M$37.9MNo debt tags$010-Q 2026-04-30
Q4 2024
2024-12-31
$0-$35.4M-$31.2M$26.7MNo debt tags$010-K 2026-02-11

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52026-09-25
Latest annual report10-K2026-02-11
Latest quarterly / interim10-Q2026-10-29
Latest current report8-K2026-10-28
Latest proxyDEFA14A2026-04-01

Source: SEC EDGAR submissions feed, 652 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+8.9%
1 month+9.6%
3 months-11.3%
Year to date-16.9%
1 year-25.1%
From 52-week high-30.6%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
ARQTArcutis Biotherapeutics Inc.$27.15-3.93%$3.4B
VRDNViridian Therapeutics Inc.$29.80-3.47%$3.4B
IRONDisc Medicine Inc.$76.59-4.26%$3.5B
ELVNEnliven Therapeutics Inc.$47.62-2.42%$3.5B
PBLSParabilis Medicines Inc.$28.45+0.07%$3.5B
AMLXAmylyx Pharmaceuticals Inc.$27.80-8.22%$3.6B
ACADACADIA Pharmaceuticals Inc.$18.67-0.43%$3.2B
ABCLAbCellera Biologics Inc. Common Shares$11.12-3.22%$3.6B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier